Evidence map›Paper›PMID 34160668›Full record

ArticleEuropean journal of clinical pharmacology2021

Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis.

Małgorzata Łączna, Damian Malinowski, Agnieszka Paradowska-Gorycka, Krzysztof Safranow, Violetta Dziedziejko, Andrzej Pawlik

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Małgorzata ŁącznaDepartment of Physiology, Pomeranian Medical University, 70-111, Szczecin, Poland.
Damian MalinowskiDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111, Szczecin, Poland.
Agnieszka Paradowska-GoryckaDepartment of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637, Warsaw, Poland.
Krzysztof SafranowDepartment of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111, Szczecin, Poland.
Violetta DziedziejkoDepartment of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111, Szczecin, Poland.
Andrzej PawlikDepartment of Physiology, Pomeranian Medical University, 70-111, Szczecin, Poland. pawand@poczta.onet.pl.ORCID http://orcid.org/0000-0001-6557-1208
Pomeranian Medical University · PLNational Institute of Geriatrics, Rheumatology and Rehabilitation · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimLeflunomide is a disease-modifying antirheumatic drug used in therapy for rheumatoid arthritis (RA). Previous studies indicated that oestrogens and androgens may affect the response to leflunomide in RA patients. The synthesis of androgens is regulated by cytochrome CYB5A. The aim of this study was to examine the association between the CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with RA.

methodsThe study included 111 women diagnosed with RA. Leflunomide was administered in monotherapy at a dose of 20 mg/day. All patients underwent a monthly evaluation for 12 months after the initiation of treatment with leflunomide.

resultsAfter 12 months of therapy, the changes in individual disease activity parameters, such as: DAS28, ESR, CRP and VAS, were not statistically significantly different between rs1790834 genotypes in the Kruskal-Wallis test.

conclusionsThe results of our study suggest lack of statistically significant association between the CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with RA.

Indexed as

AdultAgedAntirheumatic AgentsArthritis, RheumatoidCytochromes b5FemaleGenotypeHumansLeflunomideMiddle AgedPolymorphism, Single NucleotideAntirheumatic AgentsCYB5A protein, humanCytochromes b5LeflunomideCYB5ALeflunomidePolymorphismRheumatoid arthritisTherapy

Identifiers

PMID34160668
PMCPMC8528780
OpenAlexW3176136033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.